Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience by Manoj Chawla et al.
Chawla et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:20 
DOI 10.1186/s40200-015-0152-3RESEARCH ARTICLE Open AccessSafety of intravenous insulin aspart compared to
regular human insulin in patients undergoing ICU
monitoring post cardiac surgery: an Indian
experience
Manoj Chawla1*, Harshad Malve2*, Harshvi Shah1, Shwetal Shinde1 and Anil Bhoraskar1Abstract
Background: Poor perioperative glycemic control increases risk of infection, cardiovascular accidents and mortality
in patients undergoing surgery. Tight glycemic control by insulin therapy is known to yield better outcomes in such
patients. Intravenous (IV) insulin therapy with or without adjunctive subcutaneous insulin therapy is the mainstay of
managing hyperglycemia in perioperative period. This observational study assessed the safety of IV Insulin Aspart
(IAsp) as compared to Regular Human Insulin (RHI) in patients undergone cardiac surgery at a tertiary care hospital.
Methods: 203 patients received IV IAsp (n = 103) and RHI (n = 100) respectively. Safety was assessed by frequency
and severity of adverse events (AEs) & serious adverse events (SAEs) during hospitalization.
Results: IAsp effectively controlled mean blood glucose levels to 159.87 ± 41.41 mg/dl similar to RHI (160.77 ±
44.39 mg/dl). No serious adverse event was reported. The incidence of hypoglycemia was similar in both the groups.
The insulin infusion rate, time for which insulin infusion was withheld and mean blood glucose during hypoglycemia
was significantly high in RHI group.
Conclusion: This study has shown similar safety of IV IAsp as compared to IV RHI in the post cardiac surgery patients.
However physicians preferred IAsp as it offers advantage during transition. IV IAsp offers an effective and safe option
for managing hyperglycemia in patients in ICU post cardiac procedures.
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Hyperglycemia secondary to diabetes, impaired glucose
tolerance or stress-induced hyperglycemia is a common
complication in hospitalized patients [1]. It is estimated
that >30 to 50% hospitalized patients experience signifi-
cant hyperglycemia in hospitals [2]. Uncontrolled hyper-
glycemia is an important predictor of adverse hospital
outcomes, prolonged hospitalizations and accounts for
half of all health care expenditures for hospitalized pa-
tients [3,4].* Correspondence: drmanojchawla@yahoo.com; dr.harshad.malve@gmail.com
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unless otherwise stated.The prevalence of diabetes in India is increasing and
presently it is about 63 million. It is estimated to reach
around 101.2 million by the year 2030 [5]. With this in-
crease in prevalence, India faces an epidemic of Type 2
diabetes. Thus, doctors from all fields, including Intensi-
vists are more likely to face issues like hyperglycemia in
critical care settings. Inpatient hyperglycemia is com-
monly associated with increased morbidity and mortality
rates in hospitalized patients [6]. It is also well estab-
lished that perioperative glycemic control in patients
undergoing cardiac surgery reduces morbidity, infection,
myocardial or vascular dysfunction and enhances long-
term survival [7]. Intravenous (IV) insulin therapy with
subcutaneous (SC) insulin is the mainstay of treatment
in management of Hyperglycemia in hospitalized pa-
tients and has shown to improve morbidity and reduce. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients can be managed safely with SC administration of
insulin but for most experts IV administration is the pre-
ferred route because of the delayed onset of action and
prolonged half-life of SC regular insulin [9].
Faster onset and short duration of action leading to
meal time flexibility make rapid acting Insulin analogues,
particularly insulin aspart, a choice for quickly achieving
the target blood glucose levels [10]. Insulin aspart has
demonstrated a beneficial safety/efficacy ratio in patients
with Type 1 or Type 2 diabetes. When compared with
short acting human insulin, it has demonstrated a better
efficacy and safety profile [11]. Studies have shown that
insulin aspart can be used intravenously [12].
Several clinical studies with IV infusion of short acting
insulin have shown reduced morbidity and mortality in
hospitalized patients with hyperglycemia [7,13-16]. Insu-
lin aspart with a better efficacy and safety profile than
short acting human insulin has been used intravenously
and appears to be a good alternative to short acting hu-
man insulin [17-19]. Even though insulin aspart is ap-
proved for IV use, very limited data is available on its
safety and efficacy of it in a subset of Indian patients
undergoing cardiac procedures. Thus in this study we
tried to provide vital information on safety and efficacy
of insulin aspart as compared to regular human insulin
in patients undergoing ICU monitoring post cardiac sur-
gery. Also this study being an observational study pro-
vides the real life scenario on use in IV insulin in
patients undergoing cardiac procedures.
Methodology
Permission was taken from Institutional Ethics Committee
at Asian Heart institute, Mumbai, prior to initiation of the
study. In this single centre, open label, non-randomized,
observational study, 203 hospitalized patients scheduled
for cardiac procedure requiring IV insulin therapy, were
given either regular human insulin (RHI) or Insulin Aspart
(IAsp) as per the discretion of the treating physician. Phy-
sicians were free to use IV insulin infusion as per their dis-
cretion and clinical judgment. The patients were type 2
diabetes patients post-CABG (Coronary Artery Bypass
Grafting) for ICU (Intensive Care Unit) monitoring. The
patients who are unlikely to comply with protocol or aller-
gic to study insulins were excluded. Contraindications for
both the insulins were considered while selecting the pa-
tients. The patient was given an option to withdraw at will
any time during the study duration. The stopping of intra-
venous insulin therapy was at the discretion of the treating
physician, based upon the clinical evaluation.
Data was collected at baseline, while on IV insulin and
24 hours after cessation of IV insulin therapy. Before ini-
tiating IV insulin therapy, the physician gathered the
demographic data and medical history. The blood glucosemeasurements (measurements spread over 24 hours), tim-
ing and dose of IV insulin, number and type of AEs &
SAEs, number of minor and major hypoglycemic episodes,
number of rescue dextrose infusions and time for which
IV insulin was withheld due to hypoglycemia, clinical con-
dition and laboratory parameters of patients receiving in-
sulin 24 hours was noted. Following cessation of IV
insulin blood glucose measurements (at least 10, including
one at the end of 24 hours following cessation of IV insu-
lin infusion), timing and dose of substituted subcutaneous
insulin preparation, other medications administered,
number of minor and major hypoglycemic episodes,
number and type of AEs & SAEs were recorded. In
addition treating physicians entered their comments on
IV insulin therapy in a questionnaire provided to them.
All adverse events reported by the patient or physician
during IV insulin infusion were recorded on a separate
adverse event form.
Clinically acceptable range for each subject was de-
fined by the treating physician based on initial diagnosis
and the treatment target and was broadly kept at <
140 mg/dl. Minor hypoglycemic events were defined as
events with one of the following characteristics: 1) symp-
toms of hypoglycemia with confirmation by blood glu-
cose measurement < 56 mg/dl (3.1 mmol/L) and which
is handled by the subject himself/herself, or 2) any
asymptomatic blood glucose measurement < 56 mg/dl
(3.1 mmol/L). Major hypoglycemic events were defined
as events with severe central nervous system symptoms
consistent with hypoglycemia in which the subject is un-
able to treat himself/herself and has one of the following
characteristics: 1) Blood glucose < 56 mg/dl (3.1 mmol/
L), or 2) Reversal of symptoms after either carbohydrate
intake, glucagon or intravenous glucose administration.
Rescue dextrose was administered when the patient had
hypoglycemic episode.
Because of the observational nature of the study mim-
icking “real world” scenario, any procedure ordered by
the physician during this study was the one that was ap-
propriate to the routine care delivered to the patient at
the discretion of the participating physician. Patients
were under direct medical care during the entire study
period. Safety of IV insulin was assessed by monitoring
the frequency and type of adverse events (AEs) and ser-
ious adverse events (SAEs) occurred in patients on IV
insulin. Efficacy of the treatment was assessed by the
time to reach and time spent within clinically acceptable
range of blood glucose levels with IV insulin. Physicians
were asked about the reasons for preferring the specific
study insulin (IAsp or RHI) like: Quick achievement of
target blood glucose levels, Very safe to use, Easy to
switch from IV to SC or any other reasons.
The study was conducted in accordance with the princi-
ples of declaration of Helsinki and good clinical practice
Table 2 Duration of diabetes in study groups
Diabetes
duration (years)
IAsp group RHI group
n % n %
<1 years 20 19.4 29 29.0
1–5 years 29 28.2 16 16.0
5–10 years 25 24.3 19 19.0
11–20 years 20 19.4 17 17.0
>20 years 9 8.7 19 19.0
Total 103 100.0 100 100.0
Data represented as percentages. Samples are gender matched with p = 0.778.
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ethics committee approval and informed consent from all
the participants was obtained.
Statistical methods
Data was expressed as mean and standard deviation (SD)
for continuous variables, and frequency and percentages
for categorical variables. Student t test has been used to
find the significance of study parameters. Leven’s test for
homogeneity of variance has been performed to assess the
homogeneity of variance. Chi-square/Fisher Exact test has
been used to find the significance of study parameters on
categorical scale between two or more groups.
Results
Out of total 203 patients, 103 patients received IV IAsp
and 100 patients received IV RHI. Age, height, weight,
previous use of insulin therapy and diabetes duration
were similar in both the groups (Tables 1 and 2). No in-
fection or mortality was reported in the study. Physi-
cians’ preference to use either therapy did not vary as
per the baseline characteristics of the study population.
95% physicians however preferred IAsp at the end of
study. Adverse events were similar in both the groups
(Table 3). No serious adverse event was noted during the
study. Severity of adverse events was more in RHI group
as compared to IAsp group, 15 moderate level adverse
events were noted in RHI group as compared to 11 in
IAsp group (Table 3). The adverse events were unlikely
due to the study insulin therapy.
There was no significant difference in 2 groups for
hypoglycemic episodes. However insulin infusion rate,
the time for which insulin infusion was withheld and
mean blood glucose during hypoglycemic episodes was
significantly high in RHI group as compared to IAsp
group (Table 4). The amount of dextrose infused as res-
cue medication was significantly high in IAsp group
(Table 4). Mean blood glucose while the patients were
scheduled for cardiac surgery was 142.42 ± 33.05 mg/dl
and 141.94 ± 37.13 mg/dl in IAsp and RHI group re-
spectively and was not significantly different. The pa-
tients were started on IV insulin therapy and at theTable 1 Demographics and baseline characteristics of the
overall population
Parameter (Unit) IAsp group RHI group p value
Total Patients (n) 103 100
Male: Female 4.72: 1 5.25: 1 0.78
Mean age (Years) 61.18 ± 9.13 60.48 ± 8.52 0.57
Mean Height (cm) 165.44 ± 11.59 165.14 ± 10.91 0.85
Mean Weight (kg) 71.35 ± 13.17 71.91 ± 13.02 0.76
Insulin naïve patients (n) 80 73 0.52
Values for Age, height & weight are represented as Mean ± SD; Unpaired t test.cessation of IV insulin therapy the mean blood glucose
was safely controlled by IAsp (159.87 ± 41.41 mg/dl) and
RHI (160.77 ± 44.39 mg/dl) (Table 5). Time to reach and
time spent within clinically acceptable range of blood
glucose levels were similar in both the groups.
Discussion
Current guidelines recommends target Blood Glucose
(BG) level at 140–180 mg/dL in ICU [20]. In the present
study, Insulin aspart effectively lowered mean blood glu-
cose to target range and was found to be as safe and ef-
fective as regular human insulin. And as results
indicated the insulin infusion rate needed was signifi-
cantly less with IAsp as compared to RHI. Intravenous
Insulin therapy is considered the best approach for man-
aging hyperglycemia in critical patients but once patient
starts oral feeds bolus insulin is required and therefore it
is essential to switch the patients to subcutaneous insu-
lin therapy. During transition from IV to SC insulin,
basal dose needs to be reduced by 20–33% as the stress
hyperglycemia is reduced and dose has to be adjusted
accordingly [20]. Patients with only stress hyperglycemia
are subjected to a gradual reduction in the dose of their
IV insulin and finally stopped. Before discharge the pa-
tients with hyperglycemia are stabilized and usually do
not require insulin therapy. Udwadia et al. has studied
use of IV Insulin aspart and found it to be safe & effect-
ive option for management of hyperglycemia in hospitals
[19]. Most physicians (98.6%) expressed a preference to
use IAsp in the future owing to rapid achievement of
target BG, positive safety profile and convenience of
shifting from IV to SC administration [19]. The findingsTable 3 Severity of adverse events
Severity IAsp group RHI group
n % n %
Mild 34 75.6 29 65.9
Moderate 11 24.4 15 34.1
Severe 0 0.0 0 0.0
Total 45 100.0 44 100.0
Data represented as percentages.
Table 4 Comparison of hypoglycemic episode in two groups of patients
Hypoglycemic episode IAsp group (n = 103) RHI group (n = 100) p value
Minor episode 3 0 0.086
Major episode 5 3 0.497
Mean Insulin Infusion Rate (ml/hr) 0.44 ± 0.46 1.17 ± 1.15 0.0001*
Mean Blood Glucose (mg/dl) 55.67 ± 8.63 71.00 ± 8.18 0.0001*
Mean time for insulin infusion withheld (mins) 83.3 ± 36.06 140.0 0 ± 38.56 0.0001*
Mean Rescue dextrose infused (Grams) 9.05 ± 3.27 6.25 ± 0.00 0.0001*
All values represent Mean ± SD; Unpaired t test: *p < 0.001.
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Insulin aspart by Udwadia et al. and has shown better
physician preference for IAsp. In the present study we
also found more physician preference with IAsp. Also in
the present study the time for insulin infusion withheld
was significantly less with IAsp indicating better recov-
ery from hypoglycemic episodes.
The use of IAsp has no benefit when used intraven-
ously alone however it is known to be beneficial when
given with SC route. The beneficial effect of IAsp in hos-
pitals is seen once patients are transferred to subcutane-
ous insulin therapy as there is no need to change insulin
while shifting the patient from IV to SC insulin therapy
to get the advantages with SC insulin analog therapy.
And this avoids any loss or wastage of insulin which
may occur while changing the insulins. Patient can con-
tinue with the same insulin throughout the treatment i.
e. before, during & after the hospitalization or surgery.
Rapid acting analogs with their peculiar pharmacokinetic
actions of fast absorption and dispersion from the sub-
cutaneous site of injection offer rapid lowering of BG
levels. Another important benefit is the meal time flexi-
bility [21,22]. This advantage is particularly important in
hospitalized and critically ill patients who do not have a
predictable meal pattern. Patients on parenteral medical
nutrition therapy also benefits with use of rapid acting
insulins like insulin aspart as it gives better glycemic
control without causing hypoglycemia [23].
This study being an observational study, has inherent
limitations and confounding factors, such as a lack of
tightly controlled patient populations, no control groups
and susceptibility to bias. We tried to overcome the bias
for control group by adding RHI group. This study has
not focused on the data related to the cost-effectiveness
of the study insulins. Another limitation of this study
due to its observational design is the lack of a defined IV
insulin infusion protocol which mimics the real lifeTable 5 Comparison of Glucose levels
Glucose levels IAsp group (n = 103)
Before Switch to IV 142.42 ± 33.05
After switch to IV 159.87 ± 41.41
All values represent Mean ± SD; Unpaired t test.scenario however the validated protocols with demon-
strated efficacy and safety are available [24]. In this
study, use of insulin was at the physician’s discretion and
they were allowed to choose the IV insulin protocol,
which might have affected the outcomes in some pa-
tients. Use of Insulin aspart with a standardized protocol
in hospitals is studied by Bernard et al. and found to
lower the BG safely in the Emergency Department with-
out prolonging Length of Stay (LOS) [25]. The protocol
was termed as Rush Emergency Department Hypergly-
cemia Intervention (REDHI) protocol [25].
Use of insulin aspart by IV route was earlier studied by
Robinson et al. in a hyperinsulinemic hypoglycemic clamp
study and found that soluble human insulin and insulin
aspart had similar effects upon hypoglycemia-induced al-
terations in cardiac repolarization [17]. IV insulin aspart
with insulin detemir was studied by Dungan et al. to de-
termine whether an insulin algorithm could be used in a
similar manner in the setting of diabetes and stress hyper-
glycemia following cessation of IV (IV) insulin after car-
diac surgery and they found use of IV insulin aspart to be
safe in patients after cardiac surgery [26].
It is evident from earlier studies that use of insulin
aspart with standard protocol in hospitals is helpful to
achieve the desired glycemic control with better patient
outcomes in hospitalized patients. And use of Insulin
aspart is sometimes preferred to avoid change of insulin
during transition. However more data is needed to com-
pare the benefits of IV insulin aspart over regular human
insulin in such patients. Present study has shown IV In-
sulin Aspart to be safe and effective option for managing
perioperative hyperglycemia in patients undergoing car-
diac procedure however there was no significant differ-
ence in safety profiles of the study insulins.
Although it is known that there are no advantages of
insulin analogs when used intravenously, it will be im-
perative to have a comprehensive pharmacoeconomicRHI group (n = 100) p value
141.94 ± 37.13 0.515
160.77 ± 44.39 0.709
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insulin aspart as compared to regular human insulin in
the hospital settings. This will enable the clinicians to take
the rational decisions and will give the cost-effective treat-
ment option to the patients.
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